Yubo International amends share agreement to settle $819,229 in loans with World Precision Medicine

Yubo International Biotech Ltd

Gross proceeds of $819,229 from 1,638,458 shares at $0.50 will settle all outstanding loan principal and accrued interest.
Upon delivery, Company has no further repayment obligations and any liens are automatically released.
Amendment is retroactive to September 2, 2022, executed December 6, 2022, clarifying use of proceeds.
Shares issued in a registered direct offering under effective S-1 registration statement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Yubo International Biotech Ltd entered into Securities Purchase Agreement with World Precision Medicine Technology Limited valued at $819,229 (effective 2022-09-02).

Action: entry
Agreement: equity purchase
Counterparty: World Precision Medicine Technology Limited
Value: $819,229
Effective: 2022-09-02

Exact text from the filing

On September 2, 2022, Yubo International Biotech Limited, a New York Corporation (the “ Company ”) entered into a Securities Purchase Agreement with World Precision Medicine Technology Limited (the “ Purchaser ”), as further amended by an Amendment to Securities Purchase Agreement, effective as of September 2, 2022, by and between the Company and the Purchaser (as amended, the “ Securities Purchase Agreement ”), pursuant to which the Company agreed to sell and issue to the Purchaser an aggregate of 1,638,458 shares (the “ Shares ”) of Class A Common Stock, par value $0.001 per share, of the Company, at $0.50 per share, for gross proceeds of $819,229.

View on SEC.gov

Browse all material agreements →

Yubo International Biotech Ltd filing history →

Source: SEC EDGAR

accession 0001640334-22-002578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.